Literature DB >> 9652605

Insulin-sensitising agents in polycystic-ovary syndrome.

N Sattar1, Z E Hopkinson, I A Greer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652605     DOI: 10.1016/S0140-6736(05)78345-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  The ovarian androgen-producing cells: a 2001 perspective.

Authors:  Denis A Magoffin
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

Review 2.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

3.  Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

Authors:  S A R Doi; M Al-Zaid; P A Towers; C J Scott; K A S Al-Shoumer
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

Review 4.  New routes in the polycystic ovary syndrome labyrinth: a way out?

Authors:  P Moghetti; R Castello
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 5.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 6.  Insulin resistance, polycystic ovary syndrome and metformin.

Authors:  M Pugeat; P H Ducluzeau
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  C-reactive protein in obese PCOS women and the effect of metformin therapy.

Authors:  Zelija Velija-Asimi
Journal:  Bosn J Basic Med Sci       Date:  2007-02       Impact factor: 3.363

8.  Association of follistatin and cytochrome p450 side-chain cleavage enzyme with polycystic ovarian syndrome.

Authors:  Fouzia Nazir; S Inayatullah; S Jalali
Journal:  Int J Health Sci (Qassim)       Date:  2022 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.